Skip to main content
CRDF
NASDAQ Life Sciences

FDA Agrees to Phase 3 Design for Onvansertib, Boosting Cardiff Oncology's Key Drug Path

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.74
Mkt Cap
$118.271M
52W Low
$1.48
52W High
$4.555
52W Position info
18% above low
Off High info
62% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

CRDF sits 18% above its 52-week low of $1.48.

Summary

The FDA has agreed on the Phase 3 trial design for Cardiff Oncology's lead drug, Onvansertib, for first-line RAS-mutant mCRC, following promising Phase 2 results. This regulatory clarity provides a significant de-risking event for the company's pipeline and a defined path towards potential market approval. While the headline also notes a narrower Q1 loss, this financial detail was largely covered in the 10-Q and 8-K filings yesterday, which also highlighted a 'going concern' warning and short cash runway. The FDA agreement is a new and highly material positive catalyst for this small-cap biotech, potentially enhancing its long-term valuation. Investors will now closely monitor the initiation and progress of the Phase 3 trial and the company's ability to secure necessary funding.

At the time of this announcement, CRDF was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $118.3M. The 52-week trading range was $1.48 to $4.56. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

CRDF - Latest Insights

CRDF
Nov 16, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.8328
Real-time Price: $0.8358 info
Change: +$0.0030 (+0.36%) info
Market Cap: $66.344M info
CRDF
Nov 12, 2026, 4:21 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7276
Real-time Price: $0.8358 info
Change: +$0.1082 (+15%) info
Market Cap: $66.344M info
CRDF
Nov 12, 2026, 4:20 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.7276
Real-time Price: $0.8358 info
Change: +$0.1082 (+15%) info
Market Cap: $66.344M info
CRDF
Nov 12, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7695
Real-time Price: $0.8358 info
Change: +$0.0663 (+9%) info
Market Cap: $66.344M info
CRDF
Oct 27, 2026, 4:44 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8988
Real-time Price: $0.8358 info
Change: -$0.063 (-7%) info
Market Cap: $66.344M info